Hikma Pharmaceuticals Share News (HIK)

LONDON BRIEFING: London Stock Exchange benefits from market volatility

(Alliance News) - London Stock Exchange Group on Friday said results in the first half of 2022 improved, as this year's interim period had an extra month's worth of contribution from recent acquisition Refinitiv.

LONDON MARKET CLOSE: Stocks shrug off BoE's UK recession warning

(Alliance News) - Stocks in London managed to end higher on Thursday despite a bleak warning from the Bank of England regarding to outlook for the UK economy as it jacked up rates by 50 basis points.

LONDON MARKET MIDDAY: BoE hikes, expects UK recession in 4th quarter

(Alliance News) - London shares price made some gains on Thursday morning, though these fell well short of the market rise seen on mainland Europe, as traders in London showed signs of trepidation leading up to the Bank of England's interest rate decision.

Hikma revenue flat, profits tumble in first half

(Sharecast News) - Hikma shares were tumbling on Thursday morning after the pharmaceuticals company reported flat group revenue in its first half, at $1.21bn, as it slashed its guidance on its lagging generics business.

LONDON MARKET OPEN: FTSE 100 underperforms amid pre-BoE trepidation

(Alliance News) - The FTSE 100 underperformed European peers and traded sideways in early dealings on Thursday, with the Bank of England to take centre-stage during a week that so far has been dominated by tensions between the US and China.

TOP NEWS: Hikma first half hit by stiff competition for Generics

(Alliance News) - Hikma Pharmaceuticals PLC shares suffered on Thursday, as it lowered annual guidance after a poor performance in its Generics business hit half-year profit.

LONDON MARKET PRE-OPEN: Next and Serco up outlook but Hikma lowers

(Alliance News) - Stock prices in London are seen opening ever-so-slightly higher, falling short of the more convincing gains seen in Asia, with investors wary ahead of the latest Bank of England interest rate decision.

UK earnings, trading statements calendar - next 7 days

LONDON BROKER RATINGS: Trio of downgrades for Fevertree; Admiral cut

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

LONDON BROKER RATINGS: Jefferies likes Tyman; UBS cuts Beazley

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

LONDON BROKER RATINGS: JPMorgan cuts Hikma; Liberum likes Trustpilot

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

LONDON BRIEFING: M&S warns on cost hit to profit but is well placed

(Alliance News) - Marks & Spencer on Wednesday reported a swing to profit for the year ended April 2, but the clothing, homewares and food retailer cautioned on profit in the year ahead, amid the war in Ukraine and investment plans.

IN BRIEF: Hikma Pharmaceuticals Chief Executive Siggi Olafsson resigns

Hikma Pharmaceuticals PLC - London-based pharmaceutical company - Says Siggi Olafsson has resigned as chief executive officer and from the board to "pursue other opportunities." Adds he will remain available to the company until he resigns on June 24. Olafsson was appointed as CEO in 2018. Before he joined Hikma, he was president of peer firm Actavis Generics until 2014 from 2012.

LONDON BRIEFING: Barclays launches delayed GBP1 billion share buyback

(Alliance News) - Barclays said it will kick off a GBP1.00 billion share buyback programme on Tuesday. The programme, initially announced in February, had been delayed in March after the bank admitted it sold more financial products to investors than it was allowed to.

Hikma's Siggi Olafsson stands down as CEO

(Sharecast News) - Drugmaker Hikma Pharmaceuticals revealed on Tuesday that chief executive Siggi Olafsson has resigned from both the role and the company's board of directors in order to pursue other opportunities.